IMDX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -7.92%, SMA50 -10.86%, SMA200 26.77%). The stock’s 14-day RSI is 42.11 (neutral), while the ATR of 0.51 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -33.37% below its high and over 143.35% above its low. Average 10-day trading volume of 293.42 thousand shares is below the 3-month average of 380.99 thousand, indicating normal recent market interest.

Insight Molecular Diagnostics Inc. generated EPS of -$2.83 over the past year. Five-year average earnings growth is 11.82%. Wall Street analysts project EPS growth of 49.38% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $4.25. The high target offers 113.9% upside. The low target suggests -24.24% downside. The mean target is $8.42. This offers 50.09% upside. Insight Molecular Diagnostics Inc. earnings surprise history is a mixed track record. The quarter that ended May 13, 2026, missed forecasts by -54.11%. The prior quarter beat by 13.68%. Over the last six quarters, Apple has recorded several small beats. These include 8.33% in May 12, 2025.

Insight Molecular Diagnostics Inc. has 28.62 million shares outstanding. The public float is 7.78 million shares, elevated short interest at 2.05% of float. This equals 277.27 thousand shares. The short ratio is 5.46 days. Institutional investors hold 68.2% of the float. Insiders own 20.09%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Insight Molecular Diagnostics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$6.16. This means the shares are trading below this model’s fair value.

Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) closed at $5.93 USD, gaining $0.32 (5.79%) from the previous close of $5.61. The stock is currently mid-range between its 52-week high and low $2.33 and $8.51. With a market capitalization of about $159.30 million, Insight Molecular Diagnostics Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.79). Key stats such as the average daily volume over the past year has been around 376.88 thousand shares, volume is running light vs its 52-week average. Headquartered in Nashville, TN, Insight Molecular Diagnostics Inc. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Joshua Riggs, the company employs approximately 46 people and listed since December 30, 2015. OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification.

Insight Molecular Diagnostics Inc. trades at a P/E ratio of -4.05, slightly below the S&P 500 average, with a price-to-sales ratio of 77.26 and a price-to-book ratio of -18.11 indicating negative book value, which may reflect financial stress. The P/FCF stands at -5.48, also above market averages.

Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) shares are down -18.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Insight Molecular Diagnostics Inc. trading at a premium to the broader market with a P/E of -4.05. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.42, suggesting 50.09% upside. Our AI forecast model points to short-term strength (2.67% over two weeks), a medium-term fall (-83.24% over three months), and a longer-term gain (24.96% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Insight Molecular Diagnostics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.67%, with price expected at $5.76 by June 26, 2026, within a range of $5.25 to $6.25 3-Month Outlook: Projected fall of -83.24%, reaching $0.94 by September 10, 2026, with a range of $0.78 to $1.09. 1-Year Outlook: Projected gain of 24.96%, with price at $7.01 by June 11, 2027, within a range of $4.65 to $8.02.